ONCODESIGN PRECISION MEDICINE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 EUR | -4.44% |
|
-5.08% | -22.65% |
| 01-25 | Oncodesign Precision Medicine: fundraising on the horizon | CF |
| 01-25 | Oncodesign Precision Medicine Receives ERDF Fund Totalling ?2.1 Million for its Comete Program | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Oncodesign Precision Medicine specializes in the research and development of therapeutic and diagnostic solutions in the clinical and preclinical areas of medical oncology. The company aims to discover new targeted therapy molecules for cancers without current solutions, including therapy-resistant and metastatic cancers.
Calendar
25/06/2024
- Shareholders Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.465
EUR
Average target price
2.48
EUR
Spread / Average Target
+69.28%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.65% | 26.34M | |
| +22.80% | 46.4B | |
| -1.56% | 41.75B | |
| +48.83% | 41.37B | |
| -3.42% | 29.71B | |
| +10.05% | 26.01B | |
| -20.26% | 19.52B | |
| +26.72% | 12.43B | |
| +0.01% | 12.18B | |
| -0.32% | 12.13B |
- Stock Market
- Equities
- ALOPM Stock
- News Oncodesign Precision Medicine
- Oncodesign Precision Medicine to List Directly on Euronext Access + Paris
